Pancreatic Cancer Therapeutics & Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Type, By End-User By Region & Competition, 2021-2031F

Description

The Global Pancreatic Cancer Therapeutics & Diagnostics Market is projected to grow from USD 4.72 Billion in 2025 to USD 7.31 Billion by 2031, at a 7.56% CAGR. This market includes pharmaceutical treatments like chemotherapies and targeted immunotherapies, alongside advanced imaging and molecular biomarker assays for disease identification and staging. Growth is structurally driven by an expanding geriatric population and the rising global prevalence of lifestyle-related risk factors such as type 2 diabetes and obesity, necessitating increased oncological interventions. However, a significant obstacle is the persistent late-stage diagnosis, which severely limits treatment efficacy and curative surgical options for most patients. The asymptomatic nature of early-stage disease leads to poor prognoses and a restricted patient pool for new therapies, underlined by a critically low 13% five-year relative survival rate in 2025, according to the American Cancer Society, highlighting substantial clinical gaps.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 4.72 Billion
Market Size 2031	USD 7.31 Billion
CAGR 2026-2031	7.56%
Fastest Growing Segment	Treatment
Largest Market	North America

Market Driver

The primary structural catalyst for market expansion is the increasing global incidence and prevalence of pancreatic cancer, demanding urgent advancements in clinical management. As populations age and lifestyle risk factors like obesity and diabetes become more widespread, the number of patients requiring oncological intervention has steadily grown, driving demand for diagnostic screenings and therapeutic regimens. For example, the American Cancer Society reported an estimated 67,440 new cases in the United States alone in January 2025, emphasizing the critical need for scalable medical solutions. Simultaneously, the market is being transformed by novel immunotherapies and targeted therapeutic agents, shifting treatment paradigms from conventional chemotherapies towards precision oncology. Pharmaceutical pipelines increasingly leverage specific biomarkers for improved patient outcomes, with a notable breakthrough being the 83% overall response rate achieved by avutometinib and defactinib in metastatic pancreatic ductal adenocarcinoma patients, as highlighted by Verastem Oncology in May 2025. These therapeutic strides are complemented by innovations in detection, such as the FDA's breakthrough device designation for DAMO PANDA, an AI-powered model for pancreatic cancer detection, signaling a parallel commitment to enhancing early-stage diagnosis and survival prospects.

Market Challenge

A significant restriction on the commercial scalability of the Global Pancreatic Cancer Therapeutics & Diagnostics Market is the persistent challenge of late-stage diagnosis. Since the disease typically progresses without specific symptoms until metastasis, most patients are ineligible for curative surgical interventions upon identification. This delay shifts the primary clinical focus from long-term disease management to short-term palliative care, drastically compressing the therapeutic window. Consequently, sustained administration of pharmaceutical agents is hindered, reducing the total drug volume dispensed per patient compared to other chronic oncology indications. This rapid clinical decline severely limits the addressable patient pool needed for high-volume market growth. The high attrition rate means eligible patient populations for novel therapies turn over quickly, preventing developers from accumulating a stable revenue base. This trend is underscored by the narrow gap between incidence and mortality, with an estimated 51,980 pancreatic cancer deaths in the United States in 2025, according to the American Cancer Society, which directly dampens overall market valuation by making it difficult to maintain viable patient cohorts for extended regimens.

Market Trends

The emergence of KRAS-targeted therapeutic agents represents a pivotal shift in treating pancreatic ductal adenocarcinoma, specifically addressing mutations previously considered undruggable. While earlier efforts focused on rare G12C mutations, recent clinical progress has successfully targeted the more prevalent G12D variant, offering new hope for refractory cases. This trend moves beyond broad-spectrum chemotherapy to directly silence the oncogenic driver, establishing a precise mechanism of action for a larger patient subset. A notable advancement was reported by VJOncology in October 2025, where investigational KRAS G12D inhibitors demonstrated overall response rates of 30% to 50% in pre-treated patients, signifying a major leap in precision oncology and potentially a new standard of care. Simultaneously, the proliferation of liquid biopsy and blood-based biomarkers is fundamentally altering the diagnostic landscape by enabling non-invasive, early-stage detection. This trend addresses the critical need for screening tools that can identify malignancy before metastasis, significantly expanding the curative window. Developers are leveraging multi-analyte assays combining mRNA signatures with advanced algorithms for unprecedented accuracy, as exemplified by Mainz Biomed's proprietary PancAlert test achieving 100% sensitivity and 95% specificity in distinguishing pancreatic cancer patients from healthy controls in October 2025. Such high-fidelity diagnostics are essential for shifting market value from palliative management to curative interventions, driving long-term growth through increased surgical eligibility and survivorship.

Key Market Players

Myriad Genetics Inc.
Pfizer Inc.
Novartis AG
Bristol-Myers Squibb Company
AstraZeneca PLC
Amgen Inc.
Viatris Inc.
Boston Scientific Corporation
FUJIFILM Holdings Corporation
Canon Inc.
Rafael Holdings Inc

Report Scope

In this report, the Global Pancreatic Cancer Therapeutics & Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pancreatic Cancer Therapeutics & Diagnostics Market, By Type

Treatment
Diagnostics

Pancreatic Cancer Therapeutics & Diagnostics Market, By End-User

Hospital & Clinic
Ambulatory Centers
Others

Pancreatic Cancer Therapeutics & Diagnostics Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pancreatic Cancer Therapeutics & Diagnostics Market.

Available Customizations:

Global Pancreatic Cancer Therapeutics & Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Treatment {Targeted Therapies, Chemotherapy, Surgery, Other}, Diagnostics {Imaging, Biopsy, Endoscopic Ultrasound, Other})
- 5.2.2. By End-User (Hospital & Clinic, Ambulatory Centers, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2025)
5.3. Market Map

6. North America Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By End-User
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By End-User
- 6.3.2. Canada Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By End-User
- 6.3.3. Mexico Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By End-User

7. Europe Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By End-User
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By End-User
- 7.3.2. France Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By End-User
- 7.3.3. United Kingdom Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By End-User
- 7.3.4. Italy Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By End-User
- 7.3.5. Spain Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By End-User

8. Asia Pacific Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By End-User
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By End-User
- 8.3.2. India Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By End-User
- 8.3.3. Japan Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By End-User
- 8.3.4. South Korea Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By End-User
- 8.3.5. Australia Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By End-User

9. Middle East & Africa Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By End-User
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By End-User
- 9.3.2. UAE Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By End-User
- 9.3.3. South Africa Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By End-User

10. South America Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By End-User
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By End-User
- 10.3.2. Colombia Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By End-User
- 10.3.3. Argentina Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By End-User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Pancreatic Cancer Therapeutics & Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Myriad Genetics Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Pfizer Inc.
15.3. Novartis AG
15.4. Bristol-Myers Squibb Company
15.5. AstraZeneca PLC
15.6. Amgen Inc.
15.7. Viatris Inc.
15.8. Boston Scientific Corporation
15.9. FUJIFILM Holdings Corporation
15.10. Canon Inc.
15.11. Rafael Holdings Inc